https://leadxpro.com/leadxpro-produces-protein-for-covid-19-research-campaign/ 2021-11-30T15:43:13Z https://leadxpro.com/200-2/ 2021-11-30T15:47:52Z https://leadxpro.com/leadxpro-and-lundbeck-partner-for-membrane-protein-structure-research/ 2021-11-30T15:49:35Z https://leadxpro.com/leadxpro-and-astex-enter-partnership-on-membrane-protein-structure-research/ 2021-11-30T15:50:00Z https://leadxpro.com/leadxpro-licenses-cryosparc-software/ 2021-11-30T15:50:23Z https://leadxpro.com/symposium-on-drug-discovery-swissfel/ 2021-11-30T15:51:07Z https://leadxpro.com/collaboration-with-sanofi-on-cryo-em-based-structure-research/ 2021-11-30T15:51:28Z https://leadxpro.com/first-biomolecular-structure-experiment-at-swissfel/ 2021-11-23T17:05:36Z https://leadxpro.com/collaboration-with-the-university-of-zurich-on-membrane-protein-targeted-sybodies/ 2021-11-30T15:52:30Z https://leadxpro.com/collaboration-with-interax-on-new-immune-oncology-drugs/ 2021-11-30T15:52:51Z https://leadxpro.com/watch-our-2nd-anniversary-video/ 2021-11-30T15:53:13Z https://leadxpro.com/cti-grants-leadxpro-startup-label/ 2021-11-30T15:53:52Z https://leadxpro.com/basf-and-leadxpro-announce-research-collaboration/ 2021-12-06T17:19:55Z https://leadxpro.com/leadxpro-scientists-chart-the-future-of-structure-based-drug-discovery/ 2021-11-30T15:54:31Z https://leadxpro.com/leadxpro-adopts-creoptix-wave-technology-for-ligand-characterization/ 2021-11-30T15:54:54Z https://leadxpro.com/leadxpro-and-axxam-collaborate-on-novel-inflammatory-gpcr-target/ 2021-12-06T17:21:10Z https://leadxpro.com/new-operational-space-and-funding-ensures-further-growth-of-leadxpro/ 2021-11-30T15:57:27Z https://leadxpro.com/gpcr-ligand-complex-structure-within-4-months/ 2021-11-30T15:58:06Z https://leadxpro.com/transforming-drug-discovery-on-membrane-proteins%e2%80%8b/ 2021-11-30T15:37:40Z https://leadxpro.com/ccr2/ 2021-12-06T17:13:29Z https://leadxpro.com/leadxpro-enters-collaboration-on-cryo-em-based-new-lead-discovery-with-bayer/ 2021-11-30T15:58:32Z https://leadxpro.com/leadxpro-and-boehringer-ingelheim-collaborate-on-membrane-protein-drug-target/ 2021-11-23T17:07:11Z https://leadxpro.com/park-innovaare-files-building-application-for-leadxpros-future-home/ 2021-11-30T15:58:55Z https://leadxpro.com/leadxpro-celebrates-its-first-anniversary/ 2021-11-30T16:01:44Z https://leadxpro.com/leadxpro-and-paul-scherrer-institute-sign-agreement-on-beam-line-at-the-swiss-light-source/ 2021-11-30T16:02:33Z https://leadxpro.com/further-development-of-serial-crystallography/ 2021-11-30T16:02:49Z https://leadxpro.com/heptares-and-leadxpro-enter-collaboration-on-gpcr-biostructure/ 2026-03-13T14:49:41Z https://leadxpro.com/structural-biology-doors-open-at-the-european-xfel/ 2026-03-12T13:00:35Z https://leadxpro.com/strategic-alliance-with-axxam-and-mercachemsyncom/ 2021-11-30T15:33:39Z https://leadxpro.com/leadxpro-celebrates-its-5th-anniversary/ 2021-12-06T17:12:50Z https://leadxpro.com/a2b/ 2022-12-07T13:28:05Z https://leadxpro.com/trpv4/ 2021-12-06T17:11:59Z https://leadxpro.com/contact/ 2026-03-27T12:34:03Z https://leadxpro.com/therapeutics/ 2026-03-27T14:48:15Z https://leadxpro.com/first-structure-of-human-kv3-1-channel/ 2022-07-25T09:26:53Z https://leadxpro.com/cryo-em-of-lptde/ 2022-04-05T13:47:56Z https://leadxpro.com/data-privacy-imprint/ 2026-04-23T09:20:23Z https://leadxpro.com/leadxpro-joins-the-mabdesign-network/ 2022-03-23T16:54:33Z https://leadxpro.com/five-opportunities-at-the-interface-between-structural-biology-and-ai-and-their-impact-on-drug-discovery/ 2022-04-05T13:42:53Z https://leadxpro.com/colocalized-targeting-of-tgf-beta-and-pd-l1-by-bintrafusp-alfa-elicits-distinct-antitumor-responses/ 2022-11-29T15:17:56Z https://leadxpro.com/leadxpro-has-just-elucidated-the-worlds-first-structure-of-a-proton-sensing-gpcr-target/ 2023-03-15T15:07:26Z https://leadxpro.com/first-crysol-vitrojet-in-switzerland/ 2026-03-13T14:05:28Z https://leadxpro.com/septerna-engages-leadxpro-to-discover-novel-binding-partners-to-gpcr-targets-for-use-in-internal-drug-discovery-programs/ 2023-03-28T13:26:26Z https://leadxpro.com/raqualia-pharma-and-leadxpro-announce-collaboration-to-accelerate-drug-discovery-on-intractable-membrane-protein-targets/ 2023-04-25T07:53:17Z https://leadxpro.com/scientific-webinar/ 2023-06-01T16:10:58Z https://leadxpro.com/cumulus-oncology-and-leadxpro-announce-collaboration-to-develop-small-molecules-against-novel-cancer-focused-gpcr-targets/ 2023-08-17T09:11:29Z https://leadxpro.com/golgi-neurosciences-and-leadxpro-announce-collaboration-on-gpr65-modulators/ 2024-05-29T15:11:01Z https://leadxpro.com/leadxpro-and-alipheron-are-combining-their-cutting-edge-technologies-to-bring-a-new-level-of-innovation-to-early-drug-discovery/ 2024-08-29T07:31:39Z https://leadxpro.com/cumulus-oncology-and-leadxpro-achieve-critical-milestone-in-gpr68-drug-discovery-project/ 2024-08-29T07:16:00Z https://leadxpro.com/about-us/ 2026-04-17T11:57:24Z https://leadxpro.com/technology-platform/ 2026-03-27T14:32:57Z https://leadxpro.com/services/ 2026-03-27T14:40:42Z https://leadxpro.com/bd/ 2026-03-27T12:38:24Z https://leadxpro.com/new-collaboration-between-leadxpro-and-orbion/ 2025-11-28T14:24:09Z https://leadxpro.com/publications/ 2026-03-27T12:37:34Z https://leadxpro.com/ 2026-03-27T12:37:21Z https://leadxpro.com/partex-ai-and-leadxpro-announce-collaboration-to-expand-indications-and-support-out-licensing-of-a2br-antagonist-program/ 2026-01-30T15:41:51Z https://leadxpro.com/nuclera-and-leadxpro-partner-to-accelerate-structure-based-drug-design-for-complex-membrane-proteins/ 2026-02-26T09:07:00Z https://leadxpro.com/partners-test-page/ 2026-04-22T07:28:25Z https://leadxpro.com/news/ 2026-03-27T12:37:55Z https://leadxpro.com/media/ 2026-03-27T12:38:08Z https://leadxpro.com/case-studies/ 2026-03-19T10:17:30Z https://leadxpro.com/news-media/ 2026-04-24T05:53:22Z